Phase II Concurrent Durvalumab and Radiotherapy for for Stage III Non-Small Cell Lung Cancer

Part of paid clinical trials in Dallas, Texas.

Sponsor
University of Texas Southwestern Medical Center
Study ID
NCT04003246
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

Single arm, Phase II trial of concurrent Durvalumab (MEDI 4736) and radiotherapy followed by consolidative Durvalumb (MEDI 4736) for Stage III Non-Small Cell Lung Cancer (NSCLC)

Key Dates

Start date
Apr 3, 2020
Status verified
Mar 2025
Primary completion
Jun 15, 2022
Completion
Nov 5, 2024

Study Design

Enrollment
10 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Single Arm: Therapeutic Intervention
    All subjects receive the same therapeutic intervention of 1500mg intravenous durvalumab once every 4 weeks while receiving a 60 Gy/30 Fraction course of thoracic radiotherapy. After radiotherapy is complete, subjects continue to receive 1500mg intravenous durvalumab once every 4 weeks for up to one year following the start of treatment.

Primary Outcome Measure

12-Month Progression-free Survival (PFS) Time [ Time Frame: Twelve months from the study enrollment ]

Locations (1)

FacilityCityStateZIPSite coordinators
Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - DallasDallasTexas75390-

Find similar trials in Dallas, TX

By condition
Lung cancer
By specialty
OncologyLung oncologyLung disease
By research site
Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas· Dallas, TX

Related Studies